Demonstrates how lactylation of TBK1 impacts antiviral immune responses, suggesting therapeutic targets for chronic infections.
The precise control of type I interferon (IFN-I) signaling is critical for effective antiviral defense and the maintenance of immune balance. In this study, we revealed a dynamic regulatory network involving lactylation–delactylation of TANK binding kinase 1 (TBK1), a pivotal kinase of IFN-I signaling, that finely tunes antiviral immune responses. Viral infection triggers the lactylation of TBK1 at K241, which is mediated by alanyl-tRNA synthetase 1 (AARS1), which potentiates IFN-I signaling to establish an antiviral state. Notably, we identified sirtuin 6 (SIRT6) as a pivotal “eraser” responsible for reversing this process by removing TBK1 lactylation. This action initiates a stringent negative feedback loop, leading to delactylated TBK1 being targeted by the E3 ligase SIAH2 for K48-linked polyubiquitination and subsequent selective autophagic degradation via p62. In vivo experiments revealed that myeloid-specific deletion of Sirt6 in mice resulted in sustained TBK1 lactylation and increased IFN-I production during VSV infection, ultimately improving survival. This intricate regulatory circuit not only maintains an appropriate IFN-I response to prevent excessive immune activation but also highlights the potential of targeting lactylation as a novel therapeutic strategy for chronic infections and autoimmune diseases associated with TBK1 dysregulation.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: